According to a document released by all five authorities, by 2030, intelligent diagnosis and treatment assistance will be universal in basic terms across China's primary-level medical institutions, including community and village clinics. Meanwhile, hospitals at or above the second grade in China's three-tier hospital system will widely adopt AI technologies such as intelligent medical-imaging diagnosis and clinical decision-making support technologies.

According to the results of the basic research, different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Illumina said after the close of the market recently that it intends to offer approximately $650 million of convertible senior notes due 2023. Illumina also intends to grant the initial purchasers a 30-day optionto purchase up to an addition

Finnish consumer genetic testing firm Negen has turned to BC Platforms for analysis of raw genomic data for clinical reporting purposes, the companies announced recently. Under terms of the new partnership, BC Platforms will run data collect

Bio-Rad Laboratories reported after the close of the market recently that its second quarter revenues increased 14 percent year over year, driven by growth in both its Life Science and Clinical Diagnostics businesses. For the three months e

Expedeon reported today a 106 percent jump in its second quarter revenues as the biological products and services company wrapped up the integration of several recent acquisitions. For the three-month period ended June 30, Expedeon which jus

NEW YORK (GenomeWeb) Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays. The firms will develop the new assays on Illuminas next-generation sequencing inst

Illumina reported after the close of the market on Monday that its second quarter 2018 revenues rose by 25 percent year over year. The San Diego-based genomics technology company reported total Q2 revenues of $830 million, compared to $662 m

Expedeon reported today a 106 percent jump in its second quarter revenues as the biological products and services company wrapped up the integration of several recent acquisitions. For the three-month period ended June 30, Expedeon which jus

CHICAGO AACC welcomed thousands of medical professionals and healthcare leaders at the 70thAACC Annual Scientific Meeting Clinical Lab Expo from July 29 August 2. The meeting showcased advancements in clinical testing technology and researc

The global critical care diagnostics (CCD) market is estimated to have been valued at USD 837.6 million in 2015 and is expected to reach USD 1.3 billion by 2024, driven by increasing awareness among physicians, patients requirements for cost

Finnishconsumer genetic testing firm Negen has turned to BC Platforms for analysis ofraw genomic data for clinical reporting purposes, the companies announced recently. Underterms of the new partnership, BC Platforms will run data collected